Acutaas Chemicals registered a strong performance in Q1FY26. Revenue, EBITDA and PAT registered strong growth of 17%,73% and 218% respectively on YoY terms albeit from a weak base. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 23%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with...